Teleflex Inc. Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $548.3 million, a 32.3% increase year-over-year (GAAP) and a 5.1% increase on a pro forma adjusted constant currency basis.

Adjusted EPS: $1.39, down 3.5% year-over-year.

Adjusted Operating Margin: 18.1%, a decrease of 510 basis points year-over-year, attributed to tariffs, quality remediation charges, and higher operating expenses from acquisitions.

Adjusted Gross Margin: 61.4%, down 470 basis points year-over-year.

Net Leverage: Approximately 2.5x at quarter-end.

Cash and Cash Equivalents: $329.6 million, down from $402.7 million at year-end 2025.

2Strategic Updates and Business Highlights

Completed the acquisition of BIOTRONIK's Vascular Intervention business in July 2025, enhancing the coronary intervention portfolio.

Announced divestitures of the acute care, interventional urology, and OEM businesses, expected to close in the second half of 2026, aiming to create a more focused medical technology leader.

A restructuring plan is underway, anticipated to yield $50 million in annual pretax cost savings by mid-2028.

Governance changes include the nomination of Michael J. Tokich to the Board and the establishment of a new growth and operating committee.

Jason Weidman will take over as President and CEO on June 8, 2026.

3Forward Guidance and Outlook

2026 Revenue Growth: Expected pro forma adjusted constant currency growth of 4.5% to 5.5%.

Adjusted EPS Guidance: Projected range of $6.25 to $6.55 for 2026, excluding impacts from share repurchases and debt repayment.

Anticipated to begin opportunistic share repurchases of up to $1 billion in Q2 2026, funded by proceeds from strategic divestitures.

Expected improvements in operating income and margins in 2027, with a steady-state adjusted operating margin target of approximately 23%.

4Bad News, Challenges, or Points of Concern

Recall Issues: Two third-party suppliers initiated recalls affecting certain vascular and interventional kits, which may lead to elevated back orders but are not expected to significantly impact full-year revenue.

Margin Pressure: Adjusted operating and gross margins declined due to tariffs, quality remediation costs, and increased operating expenses from acquisitions.

Integration Disruption: Integration of the Vascular Intervention business has caused some sales disruption, which is expected to improve in the second half of 2026.

Stranded Costs: Approximately $90 million in stranded costs are anticipated, impacting margins until the transition service agreements are in place.

5Notable Q&A Insights

Management acknowledged the potential for slower revenue growth in Q2 due to recalls and integration challenges but remains confident in achieving accelerated growth in the latter half of 2026.

The integration of sales forces from the Vascular Intervention acquisition is primarily causing disruption, not headcount reductions.

The company is not providing specific guidance for Q2 revenue but expects to maintain overall annual guidance despite challenges.

Discussions around potential strategic transactions were addressed, with management emphasizing a commitment to shareholder value creation and openness to considering acquisition proposals.

Tariff refunds could provide upside to guidance, with approximately $33 million of tariffs included in the full-year forecast. Overall, Teleflex is navigating a transformative phase with strategic acquisitions and divestitures while facing operational challenges and margin pressures. The outlook remains cautiously optimistic, with expectations for improved performance in 2027.